Dupont Capital Management’s Starling Oncology Warrant STLNW Stock Holding History

Dupont Capital Management’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,500	Closed	-$9K	–	1771
2021 Q4	$9K	Hold	12,500	–	–	﹤0.01%	1623
2021 Q3	$16K	Hold	12,500	–	–	﹤0.01%	1578
2021 Q2	$22K	Hold	12,500	–	–	﹤0.01%	1583
2021 Q1	$15K	Hold	12,500	–	–	﹤0.01%	1519
2020 Q4	$24K	Hold	12,500	–	–	﹤0.01%	1273
2020 Q3	$27K	Hold	12,500	–	–	﹤0.01%	1232
2020 Q2	$19K	Buy	+12,500	New	+$17.9K	﹤0.01%	1337

Other funds holding STLNW

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

DCM

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

USPCM

Union Square Park Capital Management New York $278M AUM 50.01% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Dupont Capital Management's STLNW Position: Q1 2022 in Review

Dupont Capital Management sold out of Starling Oncology Warrant (STLNW) in Q1 2022, closing a stake of 12,500 shares — an estimated $9K sold.

Dupont Capital Management first reported a position in STLNW in Q2 2020 and held it in 7 quarters. The position peaked at $27K in Q3 2020. 12 funds tracked by Wall St. Rank hold STLNW as of Q1 2022.

Dupont Capital Management reported no remaining Starling Oncology Warrant position as of Q1 2022 after selling out during the quarter.
Dupont Capital Management sold 12,500 Starling Oncology Warrant shares in Q1 2022, an estimated $9K.
Dupont Capital Management first reported a position in Starling Oncology Warrant in Q2 2020 and held it in 7 quarters.
Dupont Capital Management's Starling Oncology Warrant position peaked at $27K in Q3 2020.
12 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q1 2022.

Based on Dupont Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.